Of 154 treated patients, 110 (71%) were treated with dostarlimab alone, did not receive any additional form of treatment, and did not experience disease progression of Stage II/III locally advanced rectal cancer.
Of 154 treated patients, 110 (71%) were treated with dostarlimab alone, did not receive any additional form of treatment, and did not experience disease progression of Stage II/III locally advanced rectal cancer.
Of 154 treated patients, 110...